glp 1 vs sglt2 weight loss Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain Link To And Excerpts From

Availability of data and materials The datasets generated and analyzed during the current study are not publicly available due the database is very extensive and includes data from other studies complementary to this, but are available from the corresponding author on reasonable request

Ribupatide (12-week US P1b): The S-1 summary discloses that in just 12 weeks of 8 mg dosing, subjects lost 23.6% of their weight on average (efficacy analysis) ( [6] )

A separate late-stage cardiovascular outcomes trial is ongoing

Our finding of a significant reduction in CKD progression outcome in association with GLP1-RA use is also consistent with the findings of the FLOW study 44